Black Daniel, Corbett Dean, Roberts Timothy V, Cronin Brendan, Smith Pamela J, Janakiraman D Priya, Jackson Beth E
Sunshine Eye Clinic, Birtinya, Queensland, Australia.
Auckland Eye Ltd, Auckland, New Zealand.
Clin Ophthalmol. 2020 Aug 12;14:2291-2300. doi: 10.2147/OPTH.S260925. eCollection 2020.
To evaluate the clinical handleability and acceptability of a novel preloaded intraocular lens (IOL) delivery system for implantation of the TECNIS ZCB00 IOL (Johnson & Johnson Surgical Vision, Inc., Santa Ana, CA, USA) during routine small-incision cataract surgery.
In this prospective, open-label, noncomparative, unilateral or bilateral, multicenter study, adult subjects with unilateral or bilateral cataracts scheduled for IOL implantation were enrolled. Surgeons and surgical technicians completed per-eye day-of-surgery and end-of-surgical-day questionnaires. The primary endpoint of the study was the rate of acceptable overall clinical performance of the preloaded IOL delivery system. Other endpoints included additional responses from the questionnaires, preimplantation incision size, and safety.
The study included 91 eyes that underwent cataract surgery and IOL implantation using the preloaded delivery system and were available for the 1-day postoperative visit. Five surgeons and 14 surgical technicians from four investigational sites participated in the study. The rate of acceptable overall clinical performance was 100% (91/91) of eyes, with most responses (78/91; 85.7%) being the highest possible rating of 5 (very satisfied). Favorable responses by most surgeons and surgical technicians regarding additional endpoints further highlighted the handleability and acceptability of the preloaded delivery system. No ocular adverse events or lens findings (ie, no cases of IOL instability, haptic breakage, IOL marking, or crimping) were reported.
The results of this study demonstrated that this preloaded IOL delivery system was safe and effective during routine small-incision cataract surgery.
German Clinical Trials Register identifier, DRKS00014757.
评估一种新型预装式人工晶状体(IOL)输送系统在常规小切口白内障手术中植入TECNIS ZCB00 IOL(美国加利福尼亚州圣安娜市强生手术视力公司)的临床可操作性和可接受性。
在这项前瞻性、开放标签、非对比性、单侧或双侧的多中心研究中,纳入了计划植入IOL的单侧或双侧白内障成年受试者。外科医生和手术技术人员在手术当天和手术结束时完成了每只眼睛的问卷调查。该研究的主要终点是预装式IOL输送系统总体临床性能可接受的比率。其他终点包括问卷的额外回答、植入前切口大小和安全性。
该研究包括91只使用预装式输送系统进行白内障手术和IOL植入且术后1天可进行随访的眼睛。来自四个研究地点的五名外科医生和十四名手术技术人员参与了该研究。总体临床性能可接受的比率为100%(91/91)的眼睛,大多数回答(78/91;85.7%)为最高可能评分5分(非常满意)。大多数外科医生和手术技术人员对其他终点的积极回答进一步突出了预装式输送系统的可操作性和可接受性。未报告眼部不良事件或晶状体相关发现(即无IOL不稳定、襻断裂、IOL标记或卷曲的病例)。
本研究结果表明,这种预装式IOL输送系统在常规小切口白内障手术中是安全有效的。
德国临床试验注册标识符,DRKS00014757。